RLAY — Relay Therapeutics Share Price
0.000.00%
Last trade - 00:00- $456.01m
- -$325.31m
- $10.01m
- 13
- 24
- 29
- 10
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.59 | ||
| Price to Tang. Book | 0.59 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 45.57 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -45.39% | ||
| Return on Equity | -44.15% | ||
| Operating Margin | -3722.07% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 82.65 | 3.03 | 1.38 | 25.55 | 10.01 | 4.64 | 25.07 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Relay Therapeutics Inc. is a clinical-stage precision medicine company. The Company’s initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. Its Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company’s lead product candidates, such as RLY-2608. It is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including RLY-2608. RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alphas (PI3Kα), inhibitor in clinical development. It is the lead program in its efforts to discover and develop mutant selective inhibitors of PI3Kα.
Directors
- Sanjiv Patel PRE (47)
- Donald Bergstrom EVP (49)
- Thomas Catinazzo SVF (44)
- Tara O'Meara SVP
- Charles Ferte VPR
- Brian Adams GCN (47)
- Mark Murcko DRC (61)
- Alexis Borisy IND (49)
- Linda Hill IND (64)
- Douglas Ingram IND (58)
- Dipchand Nishar IND (52)
- Jami Rubin IND (57)
- Laura Shawver IND (63)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- May 4th, 2015
- Public Since
- July 16th, 2020
- No. of Shareholders
- 32
- No. of Employees
- 261
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 169,521,849
- Address
- 399 Binney Street, 2Nd Floor, CAMBRIDGE, 02139
- Web
- https://relaytx.com/
- Phone
- +1 6173708837
- Auditors
- Ernst & Young LLP
Upcoming Events for RLAY
Relay Therapeutics Inc Annual Shareholders Meeting
Q2 2025 Relay Therapeutics Inc Earnings Release
Similar to RLAY
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
ABPRO Holdings
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
FAQ
What is the Relay Therapeutics share price?
As of Today at 22:53 UTC, shares in Relay Therapeutics are trading at $2.69. This share price information is delayed by 15 minutes.
How has the Relay Therapeutics share price performed this year?
Shares in Relay Therapeutics last closed at $2.69 and the price had moved by -56.68% over the past 365 days. In terms of relative price strength the Relay Therapeutics share price has underperformed the S&P500 Index by -59.27% over the past year.
What are the analyst and broker recommendations for Relay Therapeutics?
The overall consensus recommendation for Relay Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Relay Therapeutics dividend yield?
Relay Therapeutics does not currently pay a dividend.
Does Relay Therapeutics pay a dividend?
Relay Therapeutics does not currently pay a dividend.
When does Relay Therapeutics next pay dividends?
Relay Therapeutics does not currently pay a dividend.
How do I buy Relay Therapeutics shares?
To buy shares in Relay Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Relay Therapeutics?
As of the previous close price of $2.69, shares in Relay Therapeutics had a market capitalisation of $456.01m.
Where are Relay Therapeutics shares listed?
Here are the trading details for Relay Therapeutics:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: RLAY
What kind of share is Relay Therapeutics?
Based on an overall assessment of its quality, value and momentum Relay Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Relay Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Relay Therapeutics is $17.00. That is 531.97% above the last closing price of $2.69.
Analysts covering Relay Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$2.08 for the next financial year.
Find out moreWhat is the trend in the Relay Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Relay Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -55.71%.
As of the last closing price of $2.69, shares in Relay Therapeutics were trading -50.46% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Relay Therapeutics PE Ratio?
The Relay Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.69.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Relay Therapeutics?
Relay Therapeutics' management team is headed by:
- Sanjiv Patel - PRE
- Donald Bergstrom - EVP
- Thomas Catinazzo - SVF
- Tara O'Meara - SVP
- Charles Ferte - VPR
- Brian Adams - GCN
- Mark Murcko - DRC
- Alexis Borisy - IND
- Linda Hill - IND
- Douglas Ingram - IND
- Dipchand Nishar - IND
- Jami Rubin - IND
- Laura Shawver - IND